Slide 1: Corporate Presentation Cryosite Limited
For personal use only Corporate Presentation Cryosite Limited August 2025 ASX Code: CTE www.cryosite.com 1
Slide 2: Disclaimer
Disclaimer The following disclaimer applies to this non-confidential presentation prepared by Cryosite Limited ACN 090 919 476 (Cryosite) which is dated 21 August 2025 (Presentation). By accepting or receiving this Presentation, you acknowledge and agree to the terms set out below. Summary informati
Slide 3: The Cryosite Opportunity
The Cryosite Opportunity A market leading clinical trial and biological depot, positioned to capitalise on the For personal use only exponential global growth in Ultra-Frozen and Cryogenic storage and logistics. Over the past three years, Cryosite has invested in the human capital, equipment, operat
Slide 4: Agenda
Agenda 1. FY25 – Overview For personal use only 2. FY25 – Financial Performance 3. Ultra-Frozen and Cryogenic i. A Growth Engine ii. Global Tailwinds iii. Performance 4. FY26 – Strategic Priorities 4
Slide 5: FY25 – Another record year for Cryosite
FY25 – Another record year for Cryosite For personal use only √ Record financial performance with double digit growth across revenue, gross profit, and EBITDA √ Our strongest operational volumes and quality results √ Commenced reporting on our Ultra-Frozen and Cryogenic revenue segment √ All major c
Slide 6: FY25 – Financial Performance
FY 25 - Financial Performance A record financial performance leveraging Cryosite’s strategic Cryosite Revenue and EBITDA (AUDm FY23 to FY25) For personal use only position in Ultra-Frozen and Cryogenic storage and logistics: 16.0 +12% 14.1 Revenue $14.1m – an increase of 12% vs FY24 ($12.6m) 14.0 12
Slide 7: A Growth Engine
Ultra-Frozen and Cryogenic – A Growth Engine 2 In FY25, Cryosite commenced reporting on our new Ultra-Frozen and For personal use only Cryogenic revenue segment encompassing advanced therapies stored in temperatures ranging from -70°C to -196°C. These include: Cell and Gene Therapies (CGT) mRNA-base
Slide 8: Global Tailwinds
Ultra-Frozen and Cryogenic - Global Tailwinds Cell and Gene Therapies are a major driver of our Ultra-Frozen and Cryogenic revenue segment For personal use only This market is expected to grow significantly through the next decade as trial complexity increases and demand for compliant infrastructure
Slide 9: Performance
Ultra-Frozen and Cryogenic – Performance Revenue $1.9m – an increase of 58% vs FY24 ($1.2m) Ultra-Frozen and Cryogenic For personal use only Revenue and EBITDA (AUDm FY23 to FY25) • a cumulative increase of 150% from FY23 ($0.7m) 2.0 1.9 1.8 EBITDA $0.8m – an increase of 65% vs FY24 ($0.5m) 1.6 • A
Slide 10: FY26 – Strategic Priorities
FY26 – Strategic Priorities Securing a second premises For personal use only to meet growing client demand. Cryosite’s strong balance sheet, pre-approved funding, and robust cashflow provide the means to acquire additional site capacity without requiring a capital raise Strengthening our Ultra -Fr